Literature DB >> 9166663

B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice.

H Noorchashm1, N Noorchashm, J Kern, S Y Rostami, C F Barker, A Naji.   

Abstract

Nonobese diabetic (NOD) mice spontaneously develop an acute onset of hyperglycemia reminiscent of human type I diabetes. The disease is the end result of a mononuclear cell infiltration of pancreatic islets (insulitis), culminating in the selective destruction of islet beta-cells by autoreactive T-cells. NOD mice also exhibit defects in B-cell tolerance as manifested by the presence of autoantibodies against islet cell autoantigens. Based on the potential ability of B-cells to act as antigen presenting cells, we hypothesized that autoreactive B-cells of NOD mice may be necessary for the activation of islet reactive CD4+ T-cells. In the present study, we utilized an anti-mu antibody to induce in vivo depletion of B-cells and found that B-cell depletion completely abrogates the development of insulitis and sialitis in NOD mice. In contrast, control IgG-treated NOD mice developed insulitis and sialitis by 5 weeks of age. Additionally, the discontinuation of anti-mu chain antibody treatment led to the full restoration of the B-cell pool and the reappearance of insulitis and sialitis. Thus, we conclude that B-cells are a requisite cell population for the genesis of the inflammatory lesions of the islets of Langerhans. This finding suggests that autoreactive B-cells may act as the antigen presenting cells necessary for the initial activation of beta-cell-reactive CD4+ T-cells implicated in the pathogenesis of autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166663     DOI: 10.2337/diab.46.6.941

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  83 in total

Review 1.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  Role of stromal-cell derived factor-1 in the development of autoimmune diseases in non-obese diabetic mice.

Authors:  Khairul Matin; M Abdus Salam; Joynab Akhter; Nobuhiro Hanada; Hidenobu Senpuku
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

3.  CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

Authors:  Andrew D Vonberg; Maria Acevedo-Calado; Aaron R Cox; Susan L Pietropaolo; Roberto Gianani; Steven K Lundy; Massimo Pietropaolo
Journal:  JCI Insight       Date:  2018-12-06

Review 4.  Treating human autoimmune disease by depleting B cells.

Authors:  R J Looney
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

5.  The postnatal maternal environment influences diabetes development in nonobese diabetic mice.

Authors:  L R Washburn; H Dang; J Tian; D L Kaufman
Journal:  J Autoimmun       Date:  2007-01-04       Impact factor: 7.094

6.  Anti-Insulin B Cells Are Poised for Antigen Presentation in Type 1 Diabetes.

Authors:  Jamie L Felton; Damian Maseda; Rachel H Bonami; Chrys Hulbert; James W Thomas
Journal:  J Immunol       Date:  2018-06-27       Impact factor: 5.422

7.  Enhanced trafficking to the pancreatic lymph nodes and auto-antigen presentation capacity distinguishes peritoneal B lymphocytes in non-obese diabetic mice.

Authors:  C Alam; S Valkonen; S Ohls; K Törnqvist; A Hänninen
Journal:  Diabetologia       Date:  2009-11-22       Impact factor: 10.122

Review 8.  Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.

Authors:  C Hu; F S Wong; L Wen
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 9.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

10.  The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes.

Authors:  Stef J Bloem; Bart O Roep
Journal:  Diabetologia       Date:  2017-04-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.